Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis

NCT07546552 — Not applicable, Recruiting, 100 participants, Peter Humaidan

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT07546552
StatusRecruiting
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: none, treatment
Enrollment100 (Estimated)
SponsorPeter Humaidan (Other); collaborators: Herlev Hospital
ConditionsFemale Infertility, NF-κB Ligand, RANKL, Osteoporosis, Follicle Development
InterventionsDenosumab, PBS (Other)
Datesstart 2025-08-01, primary completion 2028-03-15 (estimated), completion 2028-03-15 (estimated), first posted 2026-04-22, last updated 2026-04-22
Locations1 site in Denmark

Related Papers Related Patents Related Grants Related Experts
All trials for Female Infertility All trials for NF-κB Ligand All trials of Denosumab All trials of PBS

-Summary

Female infertility presents a significant societal challenge that will be aggravated in the future due to delayed parenthood. Our translational research suggests that receptor activator of NF-κB ligand (RANKL) is a novel treatment target, during assisted reproductive techniques and that inhibition of this pathway may reduce the impact of aging on the ovary. RANKL is a regulator of bone health, and an antibody (denosumab) blocking RANKL activity is used clinically to treat osteoporosis. Previously, we have shown that inhibition of RANKL increases sperm production in rodents, in human tissue models, and in a subpopulation of infertile men. Now, we show that all factors of the RANKL signalling system are expressed in human and mouse ovaries. Granulosa cell-specific Rankl knockdown lowers the number of primordial follicles, which suggests that RANKL has an important role during early stages of folliculogenesis. Additionally, our data from women undergoing in vitro fertilisation show that follicular fluid concentrations of RANKL and OPG are associated with age and the number of matured follicles, and RANKL inhibition promoted maturation of human oocytes in vitro, which suggests an effect also late in folliculogenesis. Thus, the proposed project aims to: 1) Clarify the role of RANKL in ovaries of mice and humans 2) Determine the reproductive effect of modulating RANKL activity systemically or locally in mice and monkeys 3) Investigate whether manipulation of RANKL can optimise in vitro maturation and rescue of immature human oocytes and 4) Determine whether follicular fluid concentrations of soluble RANKL and OPG may serve as markers of ovarian pathophysiology. The overall aim of this project is to uncover how RANKL regulates follicle reserve and oocyte maturation during the final stages of follicle development. Thereby, determining whether this pathway may be a target for optimisation of IVF treatment and a future treatment option for female infertility.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Study groupExperimentalOther: DenosumabDENOSUMAB medical preparation
Control groupActive comparatorOther: PBSPBS medical preparation
  • Denosumab (Other): DENOSUMAB facilitates maturation of immature occytes in stage GV and MI
  • PBS (Other): PBS facilitates maturation of immature occytes in stage GV and MI

+Outcome measures

Primary outcomes

  • Evaluate and compare the reproductive phenotype of granulosa cell-specific Rankl knock down mice, global Rankl knock out mice, and a humanized RANKL mouse model treated with denosumab. [From enrollment to the end of the study]
  • Investigate the effects of manipulating RANKL activity on ovarian function in human adult ovaries ex vivo and in xenotransplanted human ovarian cortex tissue. [From enrollment to the end of the study]
  • Investigate the reproductive effect of pharmacological RANKL inhibition in higher primates [From enrollment to the end of the study]

+Eligibility

Sex: Female, ages: 18 Years to any, accepts healthy volunteers

Inclusion Criteria:

* Female in the age of 18 or above, Normal AMH-value, able to give concent

Exclusion Criteria:

* Patients who have had autotransplanted ovarian tissue

+Locations (1)

FacilityCityCountryStatus
Regionshospitalet, Skive, Midt Jylland 7800Skive, Midt JyllandDenmarkRecruiting